New drug BBD-1 shows promise for painful skin and kidney disease
NCT ID NCT07595367
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times
Summary
This study tests a new drug, BBD-1, against standard steroids for IgA vasculitis, a disease that causes purple spots on the skin, joint pain, and can damage the kidneys. The trial will enroll 30 adults with confirmed IgA vasculitis. The goal is to see if BBD-1 can clear skin spots, relieve joint pain, and protect kidney function better than current treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BBD-1 multi-target immune enhancement targeting agent
- What this could lead to
- If successful, BBD-1 could offer a new treatment option for IgA vasculitis that works faster and with fewer side effects than current steroids.
- What could go wrong
- This is a small Phase 2 trial with only 30 people, so results may not apply to everyone. Long-term safety and effectiveness are not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC REACTION (IGA) VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Forest ecological agriculture
ENROLLING_BY_INVITATIONBaltimore, Maryland, 21287, United States
-
Forest ecological agriculture
RECRUITINGLiaocheng, Shandong, 252000, China